Synthetic and Analytical Challenges of Retigabine and N-Acetyl Retigabine
Authors: Heather Lima, Uma Sreenivasan, Isil Dilek, Josh Cooper, Brian Dockery, and Genevieve Rodgers
Presented at Society of Forensic Toxicologists (SOFT), Orlando, FL, October 28-November 1, 2013
Abstract
Retigabine, or ezogabine, is an anticonvulsant used to treat partial seizures, and is marketed under the trade names Potiga© in the US and Trobalt© in the EU. Retigabine is metabolized in the liver to N-acetyl retigabine, among other metabolites. Both retigabine and N-acetyl retigabine are monitored in clinical and forensic applications and require certified reference materials (CRM’s) for accurate quantitation.
High purity neat material of each of the above compounds was vital in producing the desired CRM's. The target compounds were purified or synthesized, certified, and then formulated into reference standards. Synthetic and analytical issues will be discussed in this presentation.
High purity neat material of each of the above compounds was vital in producing the desired CRM's. The target compounds were purified or synthesized, certified, and then formulated into reference standards. Synthetic and analytical issues will be discussed in this presentation.